After Jefferies and Leerink Partners gave Exact Sciences (NASDAQ: EXAS) a Buy rating last month, the company received another Buy, this time from Robert W. Baird. Analyst Catherine Schulte maintained a Buy rating on Exact Sciences today and set a price target of $66. The company’s shares closed yesterday at $60.56, close to its 52-week high of $63.60.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of 24.8% and a 78.8% success rate. Schulte covers the Healthcare sector, focusing on stocks such as NanoString Tech, PerkinElmer, and Waters Corp.
Currently, the analyst consensus on Exact Sciences is Strong Buy and the average price target is $66, representing an 9.0% upside.
In a report issued on May 30, Jefferies also maintained a Buy rating on the stock with a $60 price target.
See today’s analyst top recommended stocks >>
Based on Exact Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $39.42 million. In comparison, last year the company had a GAAP net loss of $34.95 million.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EXAS in relation to earlier this year. Most recently, in March 2018, Graham Peter Lidgard, the CSO of EXAS bought 7,163 shares for a total of $99,995.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EXACT Sciences Corp. is a molecular diagnostics company, which is focused on the early detection and prevention of colorectal cancer. It has an intellectual property, which protects its non invasive, molecular screening technology for the detection of colorectal cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
